BioengineeringbioRxiv
CD22L Conjugation to Insulin Attenuates Insulin-Specific B cell Activation
K. D. Apley, A. S. Griffith, G. Downes…·C. J. Berkland
This paper develops insulin-CD22L conjugates to inhibit anti-insulin B cells in T1D, finding that low-valency conjugates reduce B cell activation while high-valency ones promote it.
DOI 10.1021/acs.bioconjchem.3c00391